Welcome to another edition of Weekend Wonderings. Take a minute, grab whatever you drink on a Sunday afternoon and let’s carry on.
Go ahead, I’ll wait.
First, by the end of the month, the James will open a Phase 2 clinical trial to test two drugs for the treatment of triple negative breast cancer – a very aggressive type of cancer with high rates of recurrence.
Triple negative breast cancer, which accounts for 15 to 20 percent of breast cancers, is so hard to treat because it doesn’t have any of the receptors (substances found inside cells that give rise to cancer) that existing drugs are able to fight…
Let’s hope that these trials come up with a solution, because if treatment drugs can’t “find” anything to latch onto, the treatment just becomes that more difficult.
Next, is an article written by Sameek Roychowdhury. MD, PhD about the use of genomics in clinical trials.
Gene sequencing technology called next-generation sequencing will enable oncologists to determine which of 200-plus significant genes are altered in a patient’s cancer and to use this information to guide therapy. Ohio State is among the leaders in the country in promoting and championing this precision oncology strategy.
I’m a believer in the use of genomics as both a diagnostic and a treatment approach . There are many “families” of cancer, such as breast, prostate, lung, etc., and several subsets within each family. This is not a one-size-fits-all disease. I’m very familiar with the subsets where there is no definitive cause; which leads to the disease likely being incurable. This genomics approach may get us over that hurdle.
Healthcare: Making the segue from The James/Wexner to sports, we at tBBC, most notably MaliBuckeye, have done some articles regarding concussions that result from football. Unfortunately, we in western New York have just experienced a tragedy related to these topics.
In a high school football game between Class D (small school) Westfield/Brocton and Portville last weekend, W/B running back Damon Janes was knocked unconscious in a helmet-to-helmet collision. He was, under medical care, taken from the field, and the game was immediately cancelled. On Monday, Damon James at 16 years of age, died from his injuries.
As a parent (or any person, really) this is a horrific tragedy. As a parent of a son who played high school football, this is especially gut-wrenching. The national news has been concussion occurrences / settlements in the NFL and in the NCAA, where the players are, as expected, quite large, strong and fast. Unfortunately, even at a Class D high school, the dangers of these types of injuries still exist.
My heart goes out to the Janes family, friends and his schoolmates.
Technology: On a much lighter note, I’ve recently upgraded to an iPhone. What had I been waiting for? Aside from some functional apps, the killer app, as far as I’m concerned is FaceTime, sort of a ‘Skype for iPhone” for those of you not familiar. A week and a half ago, I spent 20 minutes or so on a FaceTime call with my uncle in Ohio, just getting caught on events. On Saturday evening, during halftime of the OSU-Cal game, I made a FaceTime call to my son, to chat and do a 1st half analysis. It might be a bit of a data-eater, so I can’t see using it for every call, but it does have its uses. This is some pretty amazing stuff. I think we’ve come a long way from rotary-dial landlines.
I just had another FaceTime with my uncle on Friday evening. It was close to a half hour of chatting and “catching up”. During the conversation it occurred to me what a quantum leap in communications this is. This is way beyond the days where we had to manage our long distance minutes over land lines, or, gasp, being on party lines. This has taken us to something beyond a mere telephone conversation. With the audio and visual capabilities, this is approaching being in the same room with someone. Believe me, if you are afar from someone, especially family, this is a very good way to “be there”.
From their 1970 concert at the Isle of Wight Festival, The Moody Blues sing Melancholy Man.